MCID: BRR002
MIFTS: 44

Barrett's Adenocarcinoma malady

Categories: Cancer diseases, Gastrointestinal diseases

Aliases & Classifications for Barrett's Adenocarcinoma

Aliases & Descriptions for Barrett's Adenocarcinoma:

Name: Barrett's Adenocarcinoma 12 14 69
Adenocarcinoma Arising in Barrett's Mucosa 12
Barrett Adenocarcinoma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:7941
NCIt 47 C7027
UMLS 69 C1332460

Summaries for Barrett's Adenocarcinoma

MalaCards based summary : Barrett's Adenocarcinoma, also known as adenocarcinoma arising in barrett's mucosa, is related to bile duct clear cell adenocarcinoma and cystinosis, nephropathic. An important gene associated with Barrett's Adenocarcinoma is TP53 (Tumor Protein P53), and among its related pathways/superpathways are DNA Double-Strand Break Repair and Development HGF signaling pathway. The drugs Menthol and Prednisone have been mentioned in the context of this disorder. Affiliated tissues include heart, endothelial and bone, and related phenotypes are Increased viability with MLN4924 (a NAE inhibitor) and cellular

Related Diseases for Barrett's Adenocarcinoma

Diseases related to Barrett's Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 91)
id Related Disease Score Top Affiliating Genes
1 bile duct clear cell adenocarcinoma 10.3 PTGS2 TP53
2 cystinosis, nephropathic 10.3 ERBB2 TP53
3 lung clear cell-sugar-tumor 10.3 ERBB2 TP53
4 clear cell adenofibroma 10.3 CDKN2A TP53
5 lacrimal gland adenoid cystic carcinoma 10.3 CDKN2A TP53
6 pericardium leiomyoma 10.2 CDKN2A TP53
7 skeletal tuberculosis 10.2 CDKN2A ERBB2
8 spondylarthropathy 10.2 CDKN2A TP53
9 posterior myocardial infarction 10.2 CDKN2A ERBB2
10 lacrimal gland squamous cell carcinoma 10.2 CDKN2A TP53
11 reactive arthritis 10.2 ERBB2 PTGS2 TP53
12 adult central nervous system mature teratoma 10.2 ERBB2 TP53 XRCC1
13 brachydactyly tibial hypoplasia 10.2 CDKN2A PTGS2
14 congenital bile acid synthesis defect 10.2 ERBB2 TP53 XRCC1
15 dysembryoplastic neuroepithelial tumor 10.2 ERBB2 PTGS2 TP53
16 mycobacterium kansasii 10.2 ERCC2 TP53 XRCC1
17 urethral verrucous carcinoma 10.2 CDKN2A PTGS2 TP53
18 endometrial squamous cell carcinoma 10.2 CDKN2A TP53
19 mitochondrial encephalomyopathy 10.2 CDKN2A PTGS2 TP53
20 estrogen-receptor positive breast cancer 10.2 CDKN2A ERBB2 TP53
21 pyomyositis 10.1 CDKN2A ERBB2 TP53
22 inverted papilloma 10.1 ERBB2 OGG1
23 ornithinemia 10.1 CDKN2A PTGS2 TP53
24 breast ductal carcinoma 10.1 KRAS TP53
25 spinal muscular atrophy with progressive myoclonic epilepsy 10.1 CDKN2A PTGS2 TP53
26 mitochondrial neurogastrointestinal encephalopathy disease 10.1 KRAS TP53
27 asperger syndrome 10.1 OGG1 PTGS2 TP53
28 in situ pulmonary adenocarcinoma 10.1 CDKN2A PTGS2 TP53
29 macrocytic anemia 10.1 KRAS PTGS2
30 infantile thalamic degeneration 10.1 KRAS TP53
31 bardet-biedl syndrome 10.1 CDKN2A ERBB2 TP53
32 hepatic flexure cancer 10.1 CDKN2A TP53 XRCC1
33 fanconi anemia, complementation group q 10.1 ERCC2 OGG1 XRCC1
34 cerebrooculofacioskeletal syndrome 2 10.1 ERCC2 OGG1 XRCC1
35 ampulla of vater neoplasm 10.1 CDKN2A TP53
36 active vestibular meniere's disease 10.1 CDKN2A PTGS2
37 arthus reaction 10.1 ERBB2 KRAS TP53
38 ideomotor apraxia 10.1 KRAS PTGS2 TP53
39 extra-adrenal pheochromocytoma 10.1 KRAS PTGS2 TP53
40 congenital symblepharon 10.1 KRAS PTGS2 TP53
41 adrenal cortical carcinoma 10.1 CDKN2A TP53 XRCC1
42 fallopian tube adenocarcinoma 10.1 CDKN2A ERBB2 PTGS2 TP53
43 dental caries 10.1 ERBB2 KRAS TP53
44 nasal cavity disease 10.1 ERBB2 KRAS TP53
45 lattice corneal dystrophy 10.1 CDKN2A ERBB2 PTGS2 TP53
46 progesterone-receptor positive breast cancer 10.1 CDKN2A ERBB2 PTGS2 TP53
47 oral squamous cell carcinoma 10.1 KRAS PTGS2 TP53
48 nevoid hypermelanosis, linear and whorled 10.1 CDKN2A ERBB2 PTGS2 TP53
49 oro-mandibular-limb hypogenesis syndrome 10.1 CDKN2A ERBB2 TP53 XRCC1
50 alpha chain disease 10.0 CDKN2A ERCC2 PTGS2 TP53

Graphical network of the top 20 diseases related to Barrett's Adenocarcinoma:



Diseases related to Barrett's Adenocarcinoma

Symptoms & Phenotypes for Barrett's Adenocarcinoma

GenomeRNAi Phenotypes related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.02 ERCC2 OGG1 RAD51 TP53 XRCC1

MGI Mouse Phenotypes related to Barrett's Adenocarcinoma:

44 (show all 14)
id Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.22 ADIPOR1 CDKN2A ERBB2 ERCC2 KRAS OGG1
2 behavior/neurological MP:0005386 10.19 ADIPOR1 CDKN2A ERBB2 ERCC2 KRAS OGG1
3 growth/size/body region MP:0005378 10.15 ADIPOR1 CDKN2A ERBB2 ERCC2 KRAS PTGS2
4 homeostasis/metabolism MP:0005376 10.13 ADIPOR1 CDKN2A ERBB2 ERCC2 KRAS OGG1
5 mortality/aging MP:0010768 10.09 CDKN2A ERBB2 ERCC2 KRAS OGG1 PTGS2
6 embryo MP:0005380 10.05 CDKN2A ERBB2 KRAS PTGS2 RAD51 TP53
7 neoplasm MP:0002006 9.97 TP53 XRCC1 CDKN2A ERBB2 ERCC2 KRAS
8 liver/biliary system MP:0005370 9.93 CDKN2A KRAS OGG1 PTGS2 TP53 ADIPOR1
9 nervous system MP:0003631 9.92 ERCC2 KRAS OGG1 PTGS2 TP53 XRCC1
10 muscle MP:0005369 9.88 ADIPOR1 CDKN2A ERBB2 KRAS PTGS2 TP53
11 normal MP:0002873 9.8 ADIPOR1 ERBB2 KRAS OGG1 PTGS2 TP53
12 skeleton MP:0005390 9.5 ADIPOR1 CDKN2A ERBB2 ERCC2 KRAS PTGS2
13 pigmentation MP:0001186 9.46 CDKN2A ERCC2 KRAS TP53
14 vision/eye MP:0005391 9.1 ADIPOR1 CDKN2A ERCC2 KRAS PTGS2 TP53

Drugs & Therapeutics for Barrett's Adenocarcinoma

Drugs for Barrett's Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 235)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Menthol Approved Phase 4 2216-51-5 16666
2
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2 53-03-2 5865
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5 Protective Agents Phase 4,Phase 3,Phase 2
6 Liver Extracts Phase 4,Phase 3
7 glucocorticoids Phase 4,Phase 3,Phase 2
8 Gastrointestinal Agents Phase 4,Phase 3,Phase 2
9 Hormone Antagonists Phase 4,Phase 3,Phase 2
10 Hormones Phase 4,Phase 3,Phase 2
11 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2
12 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
13 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2
14 Prednisolone acetate Phase 4
15 Neuroprotective Agents Phase 4
16 Peripheral Nervous System Agents Phase 4,Phase 3
17 Prednisolone hemisuccinate Phase 4
18 Prednisolone phosphate Phase 4
19 Antiemetics Phase 4
20 Methylprednisolone acetate Phase 4
21 Methylprednisolone Hemisuccinate Phase 4
22 Autonomic Agents Phase 4
23
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1 23214-92-8 31703
24
Paclitaxel Approved, Vet_approved Phase 3,Phase 2,Phase 1 33069-62-4 36314
25
Cisplatin Approved Phase 3,Phase 2 15663-27-1 84093 441203 2767
26
Topotecan Approved, Investigational Phase 2, Phase 3, Phase 1 119413-54-6, 123948-87-8 60700
27
Irinotecan Approved, Investigational Phase 3,Phase 2 97682-44-5, 100286-90-6 60838
28
Tamoxifen Approved Phase 3,Phase 2 10540-29-1 2733526
29
Carboplatin Approved Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
30
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 50-18-0, 6055-19-2 2907
31
Gemcitabine Approved Phase 3,Phase 2 95058-81-4 60750
32
Flutamide Approved Phase 3,Phase 2 13311-84-7 3397
33
Goserelin Approved Phase 3,Phase 2 65807-02-5 47725 5311128
34
Bicalutamide Approved Phase 3,Phase 2 90357-06-5 56069 2375
35
Buserelin Approved Phase 3 57982-77-1
36
Zoledronic acid Approved Phase 3 118072-93-8 68740
37
Calcium carbonate Approved Phase 3 471-34-1
38
Leuprolide Approved, Investigational Phase 3,Phase 2 53714-56-0 3911 657181
39
Cetuximab Approved Phase 3,Phase 2,Phase 1 205923-56-4 56842117 2333
40
Oxaliplatin Approved, Investigational Phase 3,Phase 2 61825-94-3 5310940 9887054 6857599, 9887054 43805
41
Anastrozole Approved, Investigational Phase 3 120511-73-1 2187
42
Capecitabine Approved, Investigational Phase 3,Phase 2 154361-50-9 60953
43
Esomeprazole Approved, Investigational Phase 3 161796-78-7, 119141-88-7 4594 9579578
44
Fluorouracil Approved Phase 3,Phase 2 51-21-8 3385
45
Bevacizumab Approved, Investigational Phase 3,Phase 2,Phase 1 216974-75-3
46
Pancrelipase Approved Phase 3,Phase 2 53608-75-6
47
Levoleucovorin Approved Phase 3,Phase 2 68538-85-2
48
Metformin Approved Phase 2, Phase 3 657-24-9 14219 4091
49
Succinylcholine Approved Phase 3 306-40-1 5314
50
Exemestane Approved, Investigational Phase 3 107868-30-4 60198

Interventional clinical trials:

(show top 50) (show all 154)
id Name Status NCT ID Phase
1 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
2 Reduction in Symptomatic Esophageal Stricture Formation Completed NCT02039115 Phase 4
3 Barretts oEsophageal Resection With Steroid Therapy Trial Recruiting NCT02004782 Phase 4
4 Endoscopy Every 2 Years or Only as Needed in Monitoring Patients With Barrett Esophagus Unknown status NCT00987857 Phase 3
5 Confocal Endomicroscopy for Barrett's Esophagus Completed NCT00487695 Phase 3
6 Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer Completed NCT00003594 Phase 3
7 Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas Completed NCT00003216 Phase 3
8 S0205 Gemcitabine w/ or w/o Cetuximab as First-Line Therapy in Locally Advanced Pancreas Cancer Completed NCT00075686 Phase 3
9 Laparoscopic-Assisted Surgery Compared With Open Surgery in Treating Patients With Colon Cancer Completed NCT00002575 Phase 3
10 S0421, Docetaxel and Prednisone With or Without Atrasentan in Treating Patients With Stage IV Prostate Cancer and Bone Metastases That Did Not Respond to Previous Hormone Therapy Completed NCT00134056 Phase 3
11 Lymph Node Removal in Treating Patients With Stage I or Stage II Non-small Cell Lung Cancer Completed NCT00003831 Phase 3
12 Combination Chemotherapy With or Without Surgery in Treating Patients With Stage III Ovarian Epithelial Cancer Completed NCT00002568 Phase 3
13 Combination Chemotherapy in Treating Patients With Primary Peritoneal or Stage III Epithelial Ovarian Cancer Completed NCT00003322 Phase 3
14 Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer Completed NCT00002717 Phase 3
15 Radiation Therapy With or Without Cisplatin or Fluorouracil in Treating Patients With Cancer of the Cervix Completed NCT00003078 Phase 3
16 Combination Chemotherapy With or Without Tirapazamine in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer Completed NCT00006484 Phase 3
17 Zoledronate in Preventing Osteoporosis and Bone Fractures in Patients With Locally Advanced Nonmetastatic Prostate Cancer Undergoing Radiation Therapy and Hormone Therapy Completed NCT00329797 Phase 3
18 Prognostic Study of Metastases in Patients With Stage I, Stage II, or Stage III Non-small Cell Lung Cancer That Can Be Removed by Surgery Completed NCT00003901 Phase 3
19 Radiation Therapy Compared With Combination Chemotherapy in Treating Patients With Advanced Endometrial Cancer Completed NCT00002493 Phase 3
20 Anastrozole or Tamoxifen in Treating Postmenopausal Women With Ductal Carcinoma in Situ Who Are Undergoing Lumpectomy and Radiation Therapy Completed NCT00053898 Phase 3
21 STRETTA ,Radio Frequency Ablation (RFA) v/s Sham Therapy for the Treatment of Refractory GERD Recruiting NCT02935881 Phase 3
22 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3
23 Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Recruiting NCT02101788 Phase 2, Phase 3
24 Carboplatin, Paclitaxel and Gemcitabine Hydrochloride With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian, Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Recruiting NCT00565851 Phase 3
25 Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer Recruiting NCT02065687 Phase 2, Phase 3
26 Cediranib Maleate and Olaparib or Standard Chemotherapy in Treating Patients With Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02502266 Phase 2, Phase 3
27 Radiation Therapy With or Without Chemotherapy in Patients With Stage I or Stage II Cervical Cancer Who Previously Underwent Surgery Recruiting NCT01101451 Phase 3
28 Olaparib or Cediranib Maleate and Olaparib Compared With Standard Platinum-Based Chemotherapy in Treating Patients With Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Recruiting NCT02446600 Phase 3
29 Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer Recruiting NCT01414608 Phase 3
30 Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Recruiting NCT01272037 Phase 3
31 A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia Active, not recruiting NCT00357682 Phase 3
32 Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer Active, not recruiting NCT01196390 Phase 3
33 Nab-paclitaxel and Gemcitabine vs Gemcitabine Alone as Adjuvant Therapy for Patients With Resected Pancreatic Cancer (the "Apact" Study) Active, not recruiting NCT01964430 Phase 3
34 Enzalutamide With or Without Abiraterone and Prednisone in Treating Patients With Castration-Resistant Metastatic Prostate Cancer Active, not recruiting NCT01949337 Phase 3
35 Hormone Therapy With or Without Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Negative Breast Cancer (The TAILORx Trial) Active, not recruiting NCT00310180 Phase 3
36 Doxorubicin Hydrochloride, Cyclophosphamide, and Pacltaxel With or Without Trastuzumab in Treating Women With HER2-Positive Node-Positive or High-Risk Node-Negative Breast Cancer Active, not recruiting NCT00005970 Phase 3
37 Radiation Therapy in Treating Patients With Stage II Prostate Cancer Active, not recruiting NCT00331773 Phase 3
38 Radiation Therapy in Treating Patients With Stage II Prostate Cancer Active, not recruiting NCT00033631 Phase 3
39 Paclitaxel, Polyglutamate Paclitaxel, or Observation in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Peritoneal Cancer, or Fallopian Tube Cancer Active, not recruiting NCT00108745 Phase 3
40 Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer Active, not recruiting NCT00807768 Phase 3
41 Hormone Therapy and Radiation Therapy in Treating Patients With Prostate Cancer Active, not recruiting NCT00005044 Phase 3
42 Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Active, not recruiting NCT01041781 Phase 3
43 Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Active, not recruiting NCT01198158 Phase 3
44 Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Active, not recruiting NCT01004978 Phase 3
45 Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine With or Without Bevacizumab as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II-IV or Recurrent Stage I Epithelial Ovarian or Fallopian Tube Cancer Active, not recruiting NCT01081262 Phase 3
46 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy Active, not recruiting NCT00769379 Phase 3
47 Estrogen Replacement Therapy in Treating Women With Early-Stage Endometrial Cancer Terminated NCT00002976 Phase 3
48 Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Stage I Cancer of the Cervix Terminated NCT00054067 Phase 3
49 Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery Terminated NCT01011478 Phase 3
50 Cisplatin and Docetaxel With or Without Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Newly Diagnosed Stage III Non-Small Cell Lung Cancer Terminated NCT00113386 Phase 3

Search NIH Clinical Center for Barrett's Adenocarcinoma

Genetic Tests for Barrett's Adenocarcinoma

Anatomical Context for Barrett's Adenocarcinoma

MalaCards organs/tissues related to Barrett's Adenocarcinoma:

39
Heart, Endothelial, Bone, Lymph Node

Publications for Barrett's Adenocarcinoma

Articles related to Barrett's Adenocarcinoma:

(show top 50) (show all 98)
id Title Authors Year
1
A case of Barrett's adenocarcinoma with marked endoscopic morphological changes in Barrett's esophagus over a long follow-up period of 15a88years. ( 26946036 )
2016
2
Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma Cells. ( 27932981 )
2016
3
A case of simultaneous esophageal squamous cell carcinoma and Barrett's adenocarcinoma. ( 27220657 )
2016
4
Single center experience of endoscopic submucosal dissection (ESD) in early Barrett's adenocarcinoma. ( 25294533 )
2015
5
Volumetric laser endomicroscopy detects subsquamous Barrett's adenocarcinoma. ( 24496431 )
2014
6
STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas. ( 23912451 )
2014
7
The evil lies below the surface: Subsquamous tumor extension in Barrett's adenocarcinoma. ( 26134612 )
2014
8
Clinical outcomes of endoscopic submucosal dissection for superficial Barrett's adenocarcinoma. ( 24565073 )
2014
9
Ischemic heart disease, factor predisposing to Barrett's adenocarcinoma: A case control study. ( 25133047 )
2014
10
Targeting homologous recombination and telomerase in Barrett's adenocarcinoma: impact on telomere maintenance, genomic instability and tumor growth. ( 23604115 )
2013
11
Small Barrett's adenocarcinoma, 3 mm in size, in long-segment Barrett's esophagus detected after 4 years of follow up. ( 23617677 )
2013
12
Differences in the Characteristics of Barrett's Esophagus and Barrett's Adenocarcinoma between the United States and Japan. ( 23606979 )
2013
13
Barrett's adenocarcinoma in long-segment Barrett's esophagus successfully detected by narrow-band imaging with magnifying endoscopy. ( 23617678 )
2013
14
A second-generation 2-Methoxyestradiol prodrug is effective against Barrett's adenocarcinoma in a mouse xenograft model. ( 23288782 )
2013
15
Current status of endoscopic diagnosis and treatment of superficial Barrett's adenocarcinoma in Asia-Pacific region. ( 23617667 )
2013
16
Reduced expression of I+GlcNAc in Barrett's oesophagus adjacent to Barrett's adenocarcinoma - a possible biomarker to predict the malignant potential of Barrett's oesophagus. ( 24117499 )
2013
17
Increased expression of the 5-lipoxygenase pathway and its cellular localization in Barrett's adenocarcinoma. ( 22690932 )
2012
18
MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. ( 22365974 )
2012
19
Targeting PI3K and RAD51 in Barrett's adenocarcinoma: impact on DNA damage checkpoints, expression profile and tumor growth. ( 22399496 )
2012
20
Clinicopathological characteristics of human epidermal growth factor receptor 2-positive Barrett's adenocarcinoma. ( 23180947 )
2012
21
A rare case of Barrett's adenocarcinoma including squamous cell carcinoma component. ( 26190613 )
2011
22
Barrett's adenocarcinoma of the esophagus: better outcomes through new methods of diagnosis and treatment. ( 21629515 )
2011
23
Human Barrett's adenocarcinoma of the esophagus, associated myofibroblasts, and endothelium can arise from bone marrow-derived cells after allogeneic stem cell transplant. ( 20677919 )
2011
24
Genomic evolution in Barrett's adenocarcinoma cells: critical roles of elevated hsRAD51, homologous recombination and Alu sequences in the genome. ( 21423218 )
2011
25
How much length of the distal esophagus is removed by transhiatal approach for squamous cell carcinoma and Barrett's adenocarcinoma in Japanese patients? ( 22234066 )
2011
26
Barrett's adenocarcinoma 52 years after subtotal esophagectomy for pediatric peptic stricture. ( 20103354 )
2010
27
A case of early Barrett's adenocarcinoma repeatedly developing multiple metachronous lesions shortly after endoscopic therapy: an analysis for genetic and epigenetic alterations. ( 20650453 )
2010
28
Homogeneous EGFR amplification defines a subset of aggressive Barrett's adenocarcinomas with poor prognosis. ( 20840671 )
2010
29
Differences in the definitions used for esophageal and gastric diseases in different countries: endoscopic definition of the esophagogastric junction, the precursor of Barrett's adenocarcinoma, the definition of Barrett's esophagus, and histologic criteria for mucosal adenocarcinoma or high-grade dysplasia. ( 19828957 )
2009
30
Aspirin is not chemoprotective for Barrett's adenocarcinoma of the oesophagus in multicentre cohort. ( 19620873 )
2009
31
DNA hypermethylation regulates the expression of members of the Mu-class glutathione S-transferases and glutathione peroxidases in Barrett's adenocarcinoma. ( 18664505 )
2009
32
Genome-wide analysis of genetic alterations in Barrett's adenocarcinoma using single nucleotide polymorphism arrays. ( 18663352 )
2009
33
Results of a multimodal therapy in patients with stage IV Barrett's adenocarcinoma. ( 18802733 )
2008
34
No association between hOGG1, XRCC1, and XPD polymorphisms and risk of reflux esophagitis, Barrett's esophagus, or esophageal adenocarcinoma: results from the factors influencing the Barrett's adenocarcinoma relationship case-control study. ( 18349297 )
2008
35
Corn-derived carbohydrate inositol hexaphosphate inhibits Barrett's adenocarcinoma growth by pro-apoptotic mechanisms. ( 18202808 )
2008
36
Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. ( 18676772 )
2008
37
Immunohistochemical expression of p63 in esophageal Barrett's adenocarcinoma. ( 21479434 )
2008
38
Comparison of DNA histograms by standard flow cytometry and image cytometry on sections in Barrett's adenocarcinoma. ( 18513411 )
2008
39
Transcriptional oncogenomic hot spots in Barrett's adenocarcinomas: serial analysis of gene expression. ( 17636545 )
2007
40
Usefulness of magnifying endoscopy with narrow band imaging for the detection of specialized intestinal metaplasia in columnar-lined esophagus and Barrett's adenocarcinoma. ( 17185078 )
2007
41
Familial trends of inheritance in gastro esophageal reflux disease, Barrett's esophagus and Barrett's adenocarcinoma: 20 families. ( 17227311 )
2007
42
Lack of EGFR gene mutations in exons 19 and 21 in esophageal (Barrett's) adenocarcinomas. ( 17227303 )
2007
43
Methylation of SOCS-3 and SOCS-1 in the carcinogenesis of Barrett's adenocarcinoma. ( 17376806 )
2007
44
Angiogenic switch in Barrett's adenocarcinoma: the role of vascular endothelial growth factor. ( 16720317 )
2006
45
Overexpression of TGF-beta1 in esophageal (Barrett's) adenocarcinoma is associated with advanced stage of disease and poor prognosis. ( 16921482 )
2006
46
Familial Barrett's adenocarcinoma. ( 16542304 )
2006
47
Expression of calcium-binding proteins S100A2 and S100A4 in Barrett's adenocarcinomas. ( 17032501 )
2006
48
NO-releasing aspirin exerts stronger growth inhibitory effect on Barrett's adenocarcinoma cells than traditional aspirin. ( 17244951 )
2006
49
Expression of p53 protein in Barrett's adenocarcinoma and adenocarcinoma of the gastric cardia and antrum. ( 16375215 )
2005
50
Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma. ( 15868927 )
2005

Variations for Barrett's Adenocarcinoma

Copy number variations for Barrett's Adenocarcinoma from CNVD:

7 (show top 50) (show all 60)
id CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 39411 10 114900000 119100000 Gain ABLIM1 Barrett''s adenocarcinoma
2 39412 10 114900000 119100000 Gain AFAP1L2 Barrett''s adenocarcinoma
3 42467 10 34500000 38800000 Gain CCNY Barrett''s adenocarcinoma
4 42468 10 34500000 38800000 Gain CUL2 Barrett''s adenocarcinoma
5 65755 12 21200000 26300000 Gain SSPN Barrett''s adenocarcinoma
6 66184 12 26300000 27700000 Gain ARNTL2 Barrett''s adenocarcinoma
7 66185 12 26300000 27700000 Gain TM7SF3 Barrett''s adenocarcinoma
8 73111 12 91200000 94800000 Gain KRT19P2 Barrett''s adenocarcinoma
9 74577 13 109100000 114142980 Gain Barrett''s adenocarcinoma
10 75797 13 24400000 26700000 Gain Barrett''s adenocarcinoma
11 79796 13 77800000 86500000 Gain SOX1 Barrett''s adenocarcinoma
12 81034 14 100400000 102200000 Gain SLC25A29 Barrett''s adenocarcinoma
13 88798 14 95400000 100400000 Gain TCL1A Barrett''s adenocarcinoma
14 88799 14 95400000 100400000 Gain TCL1B Barrett''s adenocarcinoma
15 107009 17 11200000 15900000 Loss RICH2 Barrett''s adenocarcinoma
16 114436 17 47600000 54900000 Gain CUEDC1 Barrett''s adenocarcinoma
17 115246 17 55600000 58400000 Gain LRRC37A3 Barrett''s adenocarcinoma
18 116543 17 6800000 11200000 Loss MYH13 Barrett''s adenocarcinoma
19 116544 17 6800000 11200000 Loss TP53 Barrett''s adenocarcinoma
20 122243 18 54400000 57100000 Loss Barrett''s adenocarcinoma
21 125938 19 16100000 19800000 Gain AP1M1 Barrett''s adenocarcinoma
22 127254 19 30200000 37100000 Gain ZNF536 Barrett''s adenocarcinoma
23 134771 2 106700000 108600000 Gain GCC2 Barrett''s adenocarcinoma
24 141056 2 205600000 209100000 Gain Barrett''s adenocarcinoma
25 144816 2 29800000 31900000 Gain ALK Barrett''s adenocarcinoma
26 151523 20 22300000 25700000 Gain SSTR4 Barrett''s adenocarcinoma
27 151524 20 22300000 25700000 Loss CST4 Barrett''s adenocarcinoma
28 152533 20 31500000 33900000 Gain CEP250 Barrett''s adenocarcinoma
29 154854 20 49200000 54400000 Gain CBLN4 Barrett''s adenocarcinoma
30 170891 3 161200000 169200000 Gain BCHE Barrett''s adenocarcinoma
31 172565 3 184200000 186000000 Gain MAGEF1 Barrett''s adenocarcinoma
32 172566 3 184200000 186000000 Gain MUC13 Barrett''s adenocarcinoma
33 172567 3 184200000 186000000 Gain VPS8 Barrett''s adenocarcinoma
34 177566 3 58500000 63700000 Loss Barrett''s adenocarcinoma
35 196847 5 172200000 176500000 Gain MSX2 Barrett''s adenocarcinoma
36 203652 6 1 2300000 Gain Barrett''s adenocarcinoma
37 204555 6 11200000 13500000 Gain PHACTR1 Barrett''s adenocarcinoma
38 205460 6 127300000 130400000 Gain C6orf190 Barrett''s adenocarcinoma
39 205461 6 127300000 130400000 Gain PTPRK Barrett''s adenocarcinoma
40 212308 6 36800000 40600000 Gain DNAH8 Barrett''s adenocarcinoma
41 219021 7 120900000 123600000 Loss SLC13A1 Barrett''s adenocarcinoma
42 219022 7 120900000 123600000 Loss TAS2R16 Barrett''s adenocarcinoma
43 225150 7 43300000 46600000 Gain RAMP3 Barrett''s adenocarcinoma
44 225833 7 50900000 53900000 Gain Barrett''s adenocarcinoma
45 227260 7 66100000 71800000 Gain CALN1 Barrett''s adenocarcinoma
46 227261 7 66100000 71800000 Gain WBSCR17 Barrett''s adenocarcinoma
47 227796 7 7200000 13300000 Gain ICA1 Barrett''s adenocarcinoma
48 231014 8 101600000 106100000 Gain ANKRD46 Barrett''s adenocarcinoma
49 231021 8 101600000 106100000 Gain RNF19 Barrett''s adenocarcinoma
50 232059 8 110600000 112200000 Gain PKHD1L1 Barrett''s adenocarcinoma

Expression for Barrett's Adenocarcinoma

Search GEO for disease gene expression data for Barrett's Adenocarcinoma.

Pathways for Barrett's Adenocarcinoma

Pathways related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 21)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13 ERCC2 OGG1 RAD51 TP53 XRCC1
2
Show member pathways
12.58 ERBB2 KRAS PTGS2 TP53
3
Show member pathways
12.44 ERCC2 OGG1 RAD51 TP53 XRCC1
4
Show member pathways
12.31 ERBB2 KRAS RAD51 TP53
5 12.24 CDKN2A ERBB2 KRAS PTGS2 TP53
6 12.18 CDKN2A ERCC2 RAD51 TP53 XRCC1
7 12.03 CDKN2A ERBB2 KRAS PTGS2 RAD51 TP53
8 11.97 KRAS PTGS2 TP53
9
Show member pathways
11.96 ERBB2 KRAS TP53
10 11.92 KRAS RAD51 TP53
11
Show member pathways
11.88 ADIPOR1 KRAS TP53
12 11.82 CDKN2A KRAS TP53
13 11.77 CDKN2A ERBB2 KRAS TP53
14 11.72 CDKN2A KRAS TP53
15 11.5 CDKN2A ERCC2 TP53
16 11.45 ERBB2 KRAS TP53
17 11.42 CDKN2A ERBB2 KRAS TP53
18 11.32 CDKN2A ERBB2 GSTT2 TP53
19
Show member pathways
11.17 CDKN2A ERBB2 KRAS RAD51 TP53
20 10.89 CDKN2A TP53
21
Show member pathways
10.88 CDKN2A TP53

GO Terms for Barrett's Adenocarcinoma

Cellular components related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 mitochondrion GO:0005739 9.1 CDKN2A COX7A2 KRAS OGG1 RAD51 TP53

Biological processes related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 13)
id Name GO ID Score Top Affiliating Genes
1 DNA repair GO:0006281 9.76 ERCC2 OGG1 RAD51 XRCC1
2 response to drug GO:0042493 9.71 OGG1 PTGS2 RAD51 XRCC1
3 response to oxidative stress GO:0006979 9.67 ERCC2 OGG1 PTGS2
4 negative regulation of cell growth GO:0030308 9.65 ADIPOR1 CDKN2A TP53
5 cellular response to DNA damage stimulus GO:0006974 9.55 ERCC2 OGG1 RAD51 TP53 XRCC1
6 cellular response to gamma radiation GO:0071480 9.52 RAD51 TP53
7 response to X-ray GO:0010165 9.51 RAD51 TP53
8 Ras protein signal transduction GO:0007265 9.5 CDKN2A KRAS TP53
9 replicative senescence GO:0090399 9.43 CDKN2A TP53
10 positive regulation of cellular senescence GO:2000774 9.37 CDKN2A KRAS
11 negative regulation of immature T cell proliferation in thymus GO:0033088 9.26 CDKN2A ERBB2
12 nucleotide-excision repair GO:0006289 9.13 ERCC2 OGG1 TP53
13 base-excision repair GO:0006284 8.8 OGG1 TP53 XRCC1

Molecular functions related to Barrett's Adenocarcinoma according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 damaged DNA binding GO:0003684 8.8 OGG1 TP53 XRCC1

Sources for Barrett's Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....